Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery
5 novembre 2021 mis à jour par: Wake Forest University Health Sciences
Support for Optimal Recovery Following Gynecologic Surgery Study (SOARING)
This trial studies how well two different supportive programs work in supporting optimal recovery in participants undergoing gynecological surgery.
Supportive programs use different methods for helping participants cope with the surgical experience including gentle movements, counseling, writing, or relaxation techniques, and may help improve participants' well-being after gynecological surgery.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To calculate recruitment, adherence, assessment completion, and retention rates.
SECONDARY OBJECTIVES:
I. Document the frequency of adverse events. II. Assess descriptive data on proposed outcomes (i.e., pain, sleep disturbances, psychological distress) for the next phase of study.) III. Qualitatively assess acceptability to guide future study planning.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I (MINDFUL MOVEMENT AND BREATHING [eMMB]): Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
GROUP II (ATTENTION CONTROL [AC]): Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
Type d'étude
Interventionnel
Inscription (Réel)
31
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest University Health Sciences
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Femelle
La description
Inclusion Criteria:
- Scheduled for an abdominal gynecological surgery (i.e. uterine, ovarian) to remove a suspected malignancy.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1.
- Cognitively able to complete assessments as judged by the study team.
- Able to understand, read and write English.
Exclusion Criteria:
- Have schizophrenia or any other psychotic disorder.
- Have a diagnosed sleep disorder including untreated obstructive sleep apnea, periodic limb movement disorder, or restless leg syndrome.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group I (eMMB)
Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation.
This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery.
Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
|
Etudes annexes
Given information about mindful movement and breathing
|
|
Comparateur actif: Group II (AC)
Participants will receive caring attention.
This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery.
Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
|
Etudes annexes
Receive caring attention phone call
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants Retained in the Study
Délai: Up to 2 weeks
|
Will provide quantitative data to guide future study planning.
Will calculate 95% confidence intervals for each of the feasibility measures to determine the range of estimates that are consistent with the data.
Will track the number of screened participants, those who are eligible, and the percent who agree to participate.
For those not meeting the eligibility criteria, reasons will be summarized.
The proportion of participants and corresponding 95% CI for participants who participated in each group will be computed.
Will use one-sample tests of binomial proportions to compare the recruitment, adherence, and retention rates to the hypothesized values of 50%, 70% and 70%, respectively.
|
Up to 2 weeks
|
|
Percentage of Participants That Were Adhered to the Intervention
Délai: Up to 5 weeks
|
Will provide quantitative data to guide future study planning.
Will calculate 95% confidence intervals for each of the feasibility measures to determine the range of estimates that are consistent with the data.
Will track the number of screened participants, those who are eligible, and the percent who agree to participate.
For those not meeting the eligibility criteria, reasons will be summarized.
The proportion of participants and corresponding 95% CI for participants who participated in each group will be computed.
|
Up to 5 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Pain Intensity Per Patient Reported Outcomes Measurement Information System (PROMIS)
Délai: Baseline, 2 weeks and 4 weeks
|
Baseline analyses will include descriptive statistics of pain, background characteristics and other possible confounding variables by intervention group. The primary goal of the statistical analysis of these measures for this Aim will be to estimate standard deviations (SD) for use in future studies. A change in pain intensity between two or more time points (baseline, 2 weeks and 4 weeks) will be reported. The PROMIS assesses pain on a numeric rating scale from 0 (no pain) to 10 (worst imaginable pain) |
Baseline, 2 weeks and 4 weeks
|
|
Change in Affective Dimension of Pain
Délai: Baseline, 2 weeks and 4 weeks
|
The affective dimension of pain will be assessed with one item on a scale from 0 (not bad at all) to 10 (the most unpleasant feeling possible for me).
A higher score represent a higher affective dimension of pain for the participant.
A change in score between two or more time points (baseline, 2 weeks and 4 weeks) will be reported.
|
Baseline, 2 weeks and 4 weeks
|
|
Change in Pain Interference Per PROMIS Measure
Délai: Baseline, 2 weeks and 4 weeks
|
Baseline analyses will include descriptive statistics of pain, background characteristics and other possible confounding variables by intervention group.
The primary goal of the statistical analysis of these measures for this Aim will be to estimate standard deviations (SD) for use in future studies.
Additional analyses will include fitting mixed analysis of covariance (ANCOVA) models (adjustment for baseline) to model the trajectory of pain by time and group accounting for the repeated measures on a subject.
Score range is 0-100 with a higher score representing greater pain interference for the participant.
A change in score between two or more time points (baseline, 2 weeks and 4 weeks) will be reported.
|
Baseline, 2 weeks and 4 weeks
|
|
Change in Sleep Disturbances Per PROMIS Sleep Disturbance Short-form
Délai: Baseline, 2 weeks and 4 weeks
|
Baseline analyses will include descriptive statistics of pain, background characteristics and other possible confounding variables by intervention group.
The primary goal of the statistical analysis of these measures for this Aim will be to estimate standard deviations (SD) for use in future studies.
Score range is 0-100 with higher scores representing a greater sleep disturbance for participants.
A change in score between two or more time points (baseline, 2 weeks and 4 weeks) will be reported.
|
Baseline, 2 weeks and 4 weeks
|
|
Change in Psychological Distress Per PROMIS Depression
Délai: Baseline, 2 weeks and 4 weeks
|
Baseline analyses will include descriptive statistics of pain, background characteristics and other possible confounding variables by intervention group.
The primary goal of the statistical analysis of these measures for this Aim will be to estimate standard deviations (SD) for use in future studies.
Score range is 0-100 with the higher score representing greater depression in the participants.
A change in score between two or more time points (baseline, 2 weeks and 4 weeks) will be reported.
|
Baseline, 2 weeks and 4 weeks
|
|
Change in Psychological Distress Per PROMIS Anxiety
Délai: Baseline, 2 weeks and 4 weeks
|
Baseline analyses will include descriptive statistics of pain, background characteristics and other possible confounding variables by intervention group.
The primary goal of the statistical analysis of these measures for this Aim will be to estimate standard deviations (SD) for use in future studies.
Score range is 0-100 with a higher score presenting a greater level of anxiety in the participants.
A change in score between two or more time points (baseline, 2 weeks and 4 weeks) will be reported.
|
Baseline, 2 weeks and 4 weeks
|
|
Incidence of Adverse Events Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
Délai: Up to 4 weeks
|
Will describe any adverse events reported as frequencies.
|
Up to 4 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
7 décembre 2018
Achèvement primaire (Réel)
9 avril 2020
Achèvement de l'étude (Réel)
9 avril 2020
Dates d'inscription aux études
Première soumission
31 août 2018
Première soumission répondant aux critères de contrôle qualité
19 septembre 2018
Première publication (Réel)
24 septembre 2018
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 novembre 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 novembre 2021
Dernière vérification
1 novembre 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00052655
- P30CA012197 (Subvention/contrat des NIH des États-Unis)
- NCI-2018-01801 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- CCCWFU 97218 (Autre identifiant: Wake Forest University Health Sciences)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .